Citadel Advisors
TCRT icon

Citadel Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Citadel Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-325
Closed -$2.27K – 15234
2024
Q2 		$2.27K Buy
325
+280
+622% +$3.34K ﹤0.01% 13711
2024
Q1 		$811 Sell
45
-178
-80% -$3.56K ﹤0.01% 14243
2023
Q4 		$2.37K Sell
223
-261
-54% -$3.14K ﹤0.01% 13707
2023
Q3 		$9.57K Sell
484
-420
-46% -$18.1K ﹤0.01% 13118
2023
Q2 		$69.2K Buy
904
+480
+113% +$38.8K ﹤0.01% 11411
2023
Q1 		$40.1K Buy
424
+96
+29% +$9.14K ﹤0.01% 12432
2022
Q4 		$31.9K Sell
328
-77
-19% -$11.2K ﹤0.01% 12661
2022
Q3 		$104K Buy
405
+304
+301% +$88.3K ﹤0.01% 11057
2022
Q2 		$19K Buy
101
+14
+16% +$1.34K ﹤0.01% 12427
2022
Q1 		$8K Sell
87
-605
-87% -$77.7K ﹤0.01% 13400
2021
Q4 		$113K Sell
692
-300
-30% -$65.9K ﹤0.01% 12595
2021
Q3 		$271K Buy
992
+232
+31% +$70.9K ﹤0.01% 11283
2021
Q2 		$301K Sell
760
-20
-3% -$9.34K ﹤0.01% 11267
2021
Q1 		$421K Buy
780
+485
+164% +$302K ﹤0.01% 10060
2020
Q4 		$112K Sell
295
-22
-7% -$8.75K ﹤0.01% 10154
2020
Q3 		$120K Sell
317
-134
-30% -$59.2K ﹤0.01% 9163
2020
Q2 		$222K Sell
451
-54
-11% -$24.1K ﹤0.01% 8377
2020
Q1 		$185K Sell
505
-344
-41% -$178K ﹤0.01% 8088
2019
Q4 		$601K Buy
849
+70
+9% +$48.2K ﹤0.01% 6515
2019
Q3 		$500K Sell
779
-145
-16% -$115K ﹤0.01% 6753
2019
Q2 		$808K Buy
924
+385
+71% +$265K ﹤0.01% 6045
2019
Q1 		$311K Sell
539
-860
-61% -$360K ﹤0.01% 7564
2018
Q4 		$392K Buy
1,399
+409
+41% +$162K ﹤0.01% 6801
2018
Q3 		$475K Sell
990
-41
-4% -$17.6K ﹤0.01% 6781
2018
Q2 		$467K Buy
1,031
+198
+24% +$126K ﹤0.01% 6486
2018
Q1 		$490K Sell
833
-206
-20% -$128K ﹤0.01% 5919
2017
Q4 		$645K Buy
1,039
+217
+26% +$156K ﹤0.01% 5296
2017
Q3 		$757K Sell
822
-92
-10% -$81.7K ﹤0.01% 4722
2017
Q2 		$853K Sell
914
-11
-1% -$10.8K ﹤0.01% 4328
2017
Q1 		$880K Buy
925
+382
+70% +$356K ﹤0.01% 4196
2016
Q4 		$435K Sell
543
-54
-9% -$48.7K ﹤0.01% 5127
2016
Q3 		$504K Sell
597
-17
-3% -$13.7K ﹤0.01% 4838
2016
Q2 		$506K Buy
614
+359
+141% +$391K ﹤0.01% 4467
2016
Q1 		$284K Sell
255
-940
-79% -$962K ﹤0.01% 5167
2015
Q4 		$1.49M Buy
1,195
+887
+288% +$1.47M ﹤0.01% 3089
2015
Q3 		$416K Sell
308
-203
-40% -$335K ﹤0.01% 5056
2015
Q2 		$920K Buy
511
+18
+4% +$27.9K ﹤0.01% 4068
2015
Q1 		$797K Buy
493
+197
+67% +$292K ﹤0.01% 4245
2014
Q4 		$225K Buy
296
+13
+5% +$6.9K ﹤0.01% 5837
2014
Q3 		$112K Buy
283
+100
+55% +$48.2K ﹤0.01% 6304
2014
Q2 		$110K Sell
183
-2
-1% -$1.11K ﹤0.01% 6160
2014
Q1 		$127K Sell
185
-8
-4% -$5.36K ﹤0.01% 5961
2013
Q4 		$126K Buy
193
+104
+117% +$61.9K ﹤0.01% 5426
2013
Q3 		$53K Sell
89
-380
-81% -$171K ﹤0.01% 5766
2013
Q2 		$148K Buy
+469
New +$130K ﹤0.01% 4914

Other funds holding TCRT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's TCRT Position: Q1 2026 in Review

Citadel Advisors opened a new position in Alaunos Therapeutics (TCRT) in Q1 2026: 10,519 shares worth $30.1K. The stake represents ﹤0.01% of the portfolio and ranks #12570 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TCRT as recently as Q2 2024.

Citadel Advisors first reported a position in TCRT in Q2 2013 and has held it in 40 quarters since. The position peaked at $3.94M in Q2 2016. 29 funds tracked by Wall St. Rank hold TCRT as of Q1 2026.

  • Citadel Advisors held 10,519 shares of Alaunos Therapeutics worth $30.1K as of Q1 2026.
  • Alaunos Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Alaunos Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12570 holding.
  • Citadel Advisors first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 40 quarters since.
  • Citadel Advisors's Alaunos Therapeutics position peaked at $3.94M in Q2 2016.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.